{
  "docId": "019de075-f154-767b-9f07-479a2da3f64b",
  "docSlug": "d4796e91221d5758021de97ee63957e0",
  "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 58,
  "pageCount": 69,
  "prevPage": 57,
  "nextPage": 59,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to summarize the value proposition of the drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/58",
  "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b",
  "deckJsonHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b.json",
  "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-58",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "callout",
      "text": "IND-enabling studies and CMC readiness work ongoing. Additional updates expected in 1H 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59b96f0f-3a6b-4002-be7b-e6c7173c2110",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "Mechanistic Rationale: MALT1 is required for oncogenic signalling in B-cell and T-cell lymphomas",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cd697cd-a510-4916-b3ab-722ea63f157e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.3
      },
      "kind": "list",
      "text": "Target Population: May expand therapeutic options for patients with B-cell lymphomas. Confirmed activity in B-cell lymphomas with PM platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b23651-19a8-471e-b3b3-33781dc8b917",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Better Design: MALT1 protease inhibitor with significantly reduced UGT1A1 inhibition risk combined with potency and selectivity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8a50797-3d75-4a65-9b74-5128ad27979f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "title",
      "text": "Allosteric MALT1 protease inhibitor shows significant anti-proliferative activity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f07fc5c0-7b6b-491d-a066-06e8ded99981",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "‘565: Potential to avoid key class-wide safety concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d391a297-89b2-46c9-832a-6f6f2ad62c31",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "910ef949-608b-419b-a3c8-9e7e864d9901",
      "evidence": "The slide presents a problem (safety concerns), agitates it (key class-wide safety concern), and hints at a solution (allosteric MALT1 protease inhibitor).",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 69,
      "from": 8,
      "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 69,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d",
      "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.",
      "position": 1,
      "objective": "Why is Exscientia's approach to precision medicine effective?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}